Institutional members access full text with Ovid®

Share this article on:

Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOs

Ritzwoller, Debra P. PhD*; Carroll, Nikki MS*; Delate, Thomas PhD*; O’Keeffe-Rossetti, Maureen MS; Fishman, Paul A. PhD; Loggers, Elizabeth T. MD, PhD; Aiello Bowles, Erin J. MPH; Elston-Lafata, Jennifer PhD§,∥; Hornbrook, Mark C. PhD

doi: 10.1097/MLR.0b013e31824def85
Applied Methods

Background: Most data regarding medical care for cancer patients in the United States comes from Surveillance, Epidemiology and End Results-linked Medicare analyses of individuals aged 65 years or older and typically excludes Medicare Advantage enrollees.

Objectives: To assess the accuracy of chemotherapy and hormone therapy treatment data available through the Cancer Research Network’s Virtual Data Warehouse (VDW).

Research Design: Retrospective, longitudinal cohort study. Medical record-abstracted, tumor registry-indicated treatments (gold standard) were compared with VDW-indicated treatments derived from health maintenance organization pharmacy, electronic medical record, and claim-based data systems.

Subjects: Enrollees aged 18 years and older diagnosed with incident breast, colorectal, lung, or prostate cancer from 2000 through 2007.

Measures: Sensitivity, specificity, and positive predictive value were computed at 6 and 12 months after cancer diagnosis.

Results: Approximately 45% of all cancer cases (total N=23,800) were aged 64 years or younger. Overall chemotherapy sensitivity/specificities across the 3 health plans for incident breast, colorectal, lung, and prostate cancer cases were 95%/90%, 95%/93%, 93%/93%, and 85%/77%, respectively. With the exception of prostate cancer cases, overall positive predictive value ranged from 86% to 89%. Small variations in chemotherapy data accuracy existed due to cancer site and data source, whereas greater variation existed in hormone therapy capture across sites.

Conclusions: Strong concordance exists between gold standard tumor registry measures of chemotherapy receipt and Cancer Research Network VDW data. Health maintenance organization VDW data can be used for a variety of studies addressing patterns of cancer care and comparative effectiveness research that previously could only be conducted among elderly Surveillance, Epidemiology and End Results-Medicare populations.

*The Institute for Health Research, Kaiser Permanente Colorado, Denver, CO

The Center for Health Research, Kaiser Permanente Northwest, Portland, OR

The Group Health Research Institute, Seattle, WA

§Department of Social and Behavioral Health, School of Medicine, Virginia Commonwealth University, Richmond, VA

Henry Ford Health System, Detroit, MI

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.lww-medicalcare.com.

Funded by NCI Grant No. R01 CA114204, Medical Care Burden of Cancer: System and Data Issues, PI: M.C.H.; NCI Cooperative Agreement No. U19 CA79689, Increasing Effectiveness of Cancer Control Interventions (Cancer Research Network), PI: Edward H. Wagner; and NCI Grant No. RC2 CA148185, Building CER Capacity: Aligning CRN, CMS, and State Resources to Map Cancer Care, Co-PIs: Jane C. Weeks and D.P.R.

The authors declare no conflict of interest.

Reprints: Debra P. Ritzwoller, PhD, The Institute for Health Research, Kaiser Permanente Colorado, P.O. Box 378066, Denver, CO 80237-8066. E-mail: debra.ritzwoller@kp.org.

© 2013 by Lippincott Williams & Wilkins.